Thalidomide	0	11	B-Drug_or_compound
and	12	15	O
angiostatin	16	27	B-Gene_or_gene_product
inhibit	28	35	O
tumor	36	41	B-Pathological_formation
growth	42	48	O
in	49	51	O
a	52	53	O
murine	54	60	B-Organism
xenograft	61	70	O
model	71	76	O
of	77	79	O
human	80	85	B-Organism
cervical	86	94	B-Pathological_formation
cancer	95	101	I-Pathological_formation
.	101	102	O

OBJECTIVE	104	113	O
:	113	114	O
To	115	117	O
determine	118	127	O
the	128	131	O
impact	132	138	O
of	139	141	O
thalidomide	142	153	B-Drug_or_compound
and	154	157	O
angiostatin	158	169	B-Gene_or_gene_product
on	170	172	O
tumor	173	178	B-Pathological_formation
growth	179	185	O
,	185	186	O
angiogenesis	187	199	O
,	199	200	O
and	201	204	O
apoptosis	205	214	O
in	215	217	O
a	218	219	O
xenograft	220	229	O
model	230	235	O
of	236	238	O
cervical	239	247	B-Pathological_formation
cancer	248	254	I-Pathological_formation
.	254	255	O

METHODS	256	263	O
:	263	264	O
Human	265	270	B-Organism
umbilical	271	280	O
endothelial	281	292	B-Cell
cells	293	298	I-Cell
were	299	303	O
treated	304	311	O
with	312	316	O
angiostatin	317	328	B-Gene_or_gene_product
or	329	331	O
thalidomide	332	343	B-Drug_or_compound
and	344	347	O
bFGF	348	352	B-Gene_or_gene_product
-	352	353	O
induced	353	360	O
proliferation	361	374	O
was	375	378	O
assessed	379	387	O
with	388	392	O
the	393	396	O
MTT	397	400	O
assay	401	406	O
.	406	407	O

Human	408	413	B-Organism
cervical	414	422	B-Cell
cancer	423	429	I-Cell
cells	430	435	I-Cell
(	436	437	O
CaSki	437	442	B-Cell
and	443	446	O
SiHa	447	451	B-Cell
)	451	452	O
were	453	457	O
injected	458	466	O
into	467	471	O
the	472	475	O
flanks	476	482	B-Organism_subdivision
of	483	485	O
nude	486	490	B-Organism
mice	491	495	I-Organism
.	495	496	O

After	497	502	O
tumors	503	509	B-Pathological_formation
developed	510	519	O
,	519	520	O
mice	521	525	B-Organism
were	526	530	O
treated	531	538	O
with	539	543	O
angiostatin	544	555	B-Gene_or_gene_product
20	556	558	O
mg	559	561	O
/	561	562	O
kg	562	564	O
/	564	565	O
day	565	568	O
or	569	571	O
thalidomide	572	583	B-Drug_or_compound
200	584	587	O
mg	588	590	O
/	590	591	O
kg	591	593	O
/	593	594	O
day	594	597	O
for	598	601	O
30	602	604	O
days	605	609	O
.	609	610	O

Fractional	611	621	O
tumor	622	627	B-Pathological_formation
growth	628	634	O
was	635	638	O
determined	639	649	O
and	650	653	O
immunohistochemical	654	673	O
analysis	674	682	O
of	683	685	O
tumors	686	692	B-Pathological_formation
was	693	696	O
used	697	701	O
to	702	704	O
determine	705	714	O
degree	715	721	O
of	722	724	O
angiogenesis	725	737	O
.	737	738	O

TUNEL	739	744	O
assay	745	750	O
was	751	754	O
used	755	759	O
to	760	762	O
assess	763	769	O
apoptosis	770	779	O
.	779	780	O

RESULTS	781	788	O
:	788	789	O
Angiostatin	790	801	B-Gene_or_gene_product
inhibited	802	811	O
endothelial	812	823	B-Cell
cell	824	828	I-Cell
proliferation	829	842	O
by	843	845	O
50	846	848	O
-	848	849	O
60	849	851	O
%	851	852	O
.	852	853	O

Thalidomide	854	865	B-Drug_or_compound
had	866	869	O
no	870	872	O
direct	873	879	O
effect	880	886	O
on	887	889	O
endothelial	890	901	B-Cell
cells	902	907	I-Cell
.	907	908	O

Angiostatin	909	920	B-Gene_or_gene_product
and	921	924	O
thalidomide	925	936	B-Drug_or_compound
both	937	941	O
inhibited	942	951	O
tumor	952	957	B-Pathological_formation
growth	958	964	O
by	965	967	O
about	968	973	O
55	974	976	O
%	976	977	O
.	977	978	O

We	979	981	O
found	982	987	O
no	988	990	O
additive	991	999	O
or	1000	1002	O
synergistic	1003	1014	O
effect	1015	1021	O
when	1022	1026	O
the	1027	1030	O
two	1031	1034	O
agents	1035	1041	O
were	1042	1046	O
combined	1047	1055	O
.	1055	1056	O

Both	1057	1061	O
agents	1062	1068	O
inhibited	1069	1078	O
angiogenesis	1079	1091	O
and	1092	1095	O
induced	1096	1103	O
apoptosis	1104	1113	O
when	1114	1118	O
compared	1119	1127	O
to	1128	1130	O
tumors	1131	1137	B-Pathological_formation
from	1138	1142	O
control	1143	1150	O
animals	1151	1158	O
.	1158	1159	O

CONCLUSIONS	1160	1171	O
:	1171	1172	O
Angiostatin	1173	1184	B-Gene_or_gene_product
and	1185	1188	O
thalidomide	1189	1200	B-Drug_or_compound
inhibit	1201	1208	O
tumor	1209	1214	B-Pathological_formation
growth	1215	1221	O
,	1221	1222	O
angiogenesis	1223	1235	O
,	1235	1236	O
and	1237	1240	O
induce	1241	1247	O
apoptosis	1248	1257	O
in	1258	1260	O
this	1261	1265	O
xenograft	1266	1275	O
model	1276	1281	O
of	1282	1284	O
cervical	1285	1293	B-Pathological_formation
cancer	1294	1300	I-Pathological_formation
.	1300	1301	O

